Metabolic syndrome in polycystic ovary syndrome: a review
Abstract
Polycystic ovary syndrome is one of the most common endocrine abnormalities in women. It affects both reproductive life and overall health of the women including metabolic abnormalities. A multidisciplinary approach is needed in those with metabolic variations to prevent them from the long-term complications like cardiovascular diseases and diabetes mellitus. The objective of this article is to review the association between PCOS and metabolic syndrome.
Keywords
Full Text:
PDFReferences
Trikudanathan S. Polycystic ovarian syndrome. Med Clin North Am. 2015;99(1):221-35.
Rasquin Leon LI, Mayrin JV. Polycystic Ovarian Disease. Treasure Island (FL): StatPearls Publishing; 2020.
Ndefo UA, Eaton A, Green MR. Polycystic ovary syndrome: a review of treatment options with a focus on pharmacological approaches. Pharmac Therapeut. 2013;38(6):336.
Ding DC, Chen W, Wang JH, Lin SZ. Association between polycystic ovarian syndrome and endometrial, ovarian, and breast cancer: A population-based cohort study in Taiwan. Medicine. 2018;97(39).
Pelusi B, Gambineri A, Pasquali R. Type 2 diabetes and the polycystic ovary syndrome. Minerva Ginecol. 2004;56(1):41-51.
Rojas J, Chávez M, Olivar L, Rojas M, Morillo J, Mejías J, Calvo M, Bermúdez V. Polycystic ovary syndrome, insulin resistance, and obesity: navigating the pathophysiologic labyrinth. Int J Reproduct Medic. 2014;2014.
Chandrasekaran S, Sagili H. Metabolic syndrome in women with polycystic ovary syndrome. Obstet Gynaecolo. 2018;20(4):245-52
Glueck CJ, Goldenberg N. Characteristics of obesity in polycystic ovary syndrome: etiology, treatment, and genetics. Metabolism. 2019;92:108-20.
Wang ET, Calderon-Margalit R, Cedars MI, Daviglus ML, Merkin SS, Schreiner PJ, Sternfeld B, Wellons M, Schwartz SM, Lewis CE, Williams OD. Polycystic ovary syndrome and risk for long-term diabetes and dyslipidemia. Obstet Gynecol. 2011;117(1):6.
Swarup S, Goyal A, Grigorova Y, et al. Metabolic Syndrome. In: StatPearls. Treasure Island: StatPearls Publishing; 2020.
Takamiya T, Zaky WR, Edmundowics D, Kadowaki T, Ueshima H, Kuller LH, et al. World Health Organization-defined metabolic syndrome is a better predictor of coronary calcium than the adult treatment panel III criteria in American men aged 40–49 years. Diabet Car. 2004;27(12):2977-9.
Saif-Ali R, Kamaruddin NA, Molham AH, Al-Dubai SA, Ngah WZ. Relationship of metabolic syndrome defined by IDF or revised NCEP ATP III with glycemic control among Malaysians with Type 2 Diabetes. Diabetol Metabol Syndro. 2020;12(1):1-7.
Rajska A, Buszewska-Forajta M, Rachoń D, Markuszewski MJ. Metabolomic insight into polycystic ovary syndrome—An overview. Int J Molecul Sci. 2020;21(14):4853.
Fenwick PH, Jeejeebhoy K, Dhaliwal R, Royall D, Brauer P, Tremblay A, Klein D, Mutch DM. Lifestyle genomics and the metabolic syndrome: A review of genetic variants that influence response to diet and exercise interventions. Crit Rev Food Sci Nutr. 2019;59(13):2028-39.
Khan Y, Lalchandani A, Gupta AC, Khadanga S, Kumar S. Prevalence of metabolic syndrome crossing 40% in Northern India: Time to act fast before it runs out of proportions. J Fam Medicine Prim Care. 2018;7(1):118.
De Meyts P. The insulin receptor and its signal transduction network. InEndotext. 2016.
Foroozanfard F, Moosavi SG, Mansouri F, Bazarganipour F. Obstetric and neonatal outcome in PCOS with gestational diabetes mellitus. J Fam Reproduct Heal. 2014;8(1):7.
Kim JJ, Choi YM. Dyslipidemia in women with polycystic ovary syndrome. Obstet Gynecol Sci. 2013;56(3):137-42.
Amiri M, Tehrani FR, Behboudi-Gandevani S, Bidhendi-Yarandi R, Carmina E. Risk of hypertension in women with polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression. Reproduct Biol Endocrinol. 2020;18(1):1-5.
Ożegowska K, Bogacz A, Bartkowiak‑Wieczorek J, Seremak‑Mrozikiewicz A, Pawelczyk L. Association between the angiotensin converting enzyme gene insertion/deletion polymorphism and metabolic disturbances in women with polycystic ovary syndrome. Molecul Medic Rep. 2016;14(6):5401-7.
De Groot PC, Dekkers OM, Romijn JA, Dieben SW, Helmerhorst FM. PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis. Hum Reproduct Update. 2011;17(4):495-500.
Ohashi K, Ouchi N, Matsuzawa Y. Adiponectin and hypertension. Am J Hypertens. 2011;24(3):263-9.
Sasaki A, Emi Y, Matsuda M, Kamada Y, Chekir C, Hiramatsu Y, Nakatsuka M. Increased arterial stiffness in mildly‐hypertensive women with polycystic ovary syndrome. J Obstet Gynaecol Res. 2011;37(5):402-11.
Mannerås-Holm L, Baghaei F, Holm G, Janson PO, Ohlsson C, Lönn M, Stener-Victorin E. Coagulation and fibrinolytic disturbances in women with polycystic ovary syndrome. J Clinic Endocrinol Metabol. 2011;96(4):1068-76.
Studen KB, Pfeifer M. Cardiometabolic risk in polycystic ovary syndrome. Endocr Connect. 2018;7(7):R238-51.
Dalle Grave R, Calugi S, Centis E, Marzocchi R, El Ghoch M, Marchesini G. Lifestyle modification in the management of the metabolic syndrome: achievements and challenges. Diabet Metabol Syndrom Obes. 2010;3:373.
Marvasti TB, Adeli KH. Pharmacological management of metabolic syndrome and its lipid complications. J Pharmaceut Sci. 2010;18(3):146.
Srinivasan K. Dietary spices as beneficial modulators of lipid profile in conditions of metabolic disorders and diseases. Food Funct. 2013;4(4):503-21.